The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
6
1 dose oral solution
Research Site
Cheshire, United Kingdom
Excretion (rate and extent) of radioactivity in urine and faeces following oral administration of [14C]AZD2066
Time frame: Until >90% of predicted total radioactivity has been recovered
Pharmacokinetics of total radioactivity in plasma and unchanged AZD2066 in plasma
Time frame: Sampling at defined timepoints during residential period from pre-dose until 168h post-dose.
Metabolite profile in plasma and excreta
Time frame: Sampling at defined timepoints during residential period from pre-dose until 48h post-dose.
AZD2066 metabolites in plasma+excreta if feasable
Time frame: Sampling at defined timepoints during residential period from pre-dose until 48h post-dose.
Safety and tolerability of AZD2066 by assessment of vital signs, laboratory variables, ECG and adverse events
Time frame: Assessments taken at visit 1 (enrolment), defined time points pre dose and post dose during visit 2 (residential period) and follow up visit 3.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.